MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

523.47 1.03

Buy Sell

Overview

Share price change

24h

Current

Min

511.24

Max

524.21

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+35.62% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.7B 12B
Previous open	522.44
Previous close	523.47

News Sentiment

By Acuity

50%

161 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 kwi 2026, 00:00 UTC

Major News Events

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10 kwi 2026, 00:00 UTC

Major News Events

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9 kwi 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 kwi 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 kwi 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9 kwi 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 kwi 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 kwi 2026, 22:31 UTC

Major News Events

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 kwi 2026, 22:31 UTC

Major News Events

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 kwi 2026, 20:57 UTC

Major News Events

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 kwi 2026, 20:55 UTC

Earnings

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 kwi 2026, 20:55 UTC

Earnings

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 kwi 2026, 20:55 UTC

Earnings

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 kwi 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 kwi 2026, 20:25 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 kwi 2026, 19:30 UTC

Major News Events

How Digital Currencies Have Helped Iran -- WSJ

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

35.62% upside

12 Months Forecast

Average 704.88 USD 35.62%

High 964 USD

Low 529 USD

Based on 9 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

161 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.